A carregar...

RAS testing in metastatic colorectal cancer: advances in Europe

Personalized medicine shows promise for maximizing efficacy and minimizing toxicity of anti-cancer treatment. KRAS exon 2 mutations are predictive of resistance to epidermal growth factor receptor-directed monoclonal antibodies in patients with metastatic colorectal cancer. Recent studies have shown...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Virchows Arch
Main Authors: Van Krieken, J Han JM, Rouleau, Etienne, Ligtenberg, Marjolijn J. L., Normanno, Nicola, Patterson, Scott D., Jung, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830882/
https://ncbi.nlm.nih.gov/pubmed/26573425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00428-015-1876-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!